Maze Therapeutics (MAZE) Net Margin (2024 - 2026)

Maze Therapeutics' (MAZE) quarterly Net Margin came in at 121.04% in Q1 2026, down 3380.95% quarter-over-quarter from 3.69% in Q4 2024.

Maze Therapeutics (MAZE) Net Margin (2024 - 2026) Analysis & Trends

Maze Therapeutics has disclosed Net Margin across 2 years of filings, most recently posting 121.04% for Q1 2026.

Net Margin for Q1 2026 came in at 121.04%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 612.71% (changed N/A YoY), and the FY2024 annual result was 22.7%, changed N/A from the prior year.
Net Margin came in at 121.04% for Q1 2026 at Maze Therapeutics, down from 3.69% in the prior quarter.
In the past five years, Net Margin ranged from a high of 9.26% in Q2 2024 to a low of 990.08% in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	0.82%
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	34.53%
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Maze Therapeutics	1.31 Bn	1.31 Bn	18.21 Mn	-121.04%

Download Data